Collegium, BioDelivery To Combine Pain Portfolios In Proposed Merger
Collegium has offered a 54% share premium to acquire competitor BioDelivery, in an offer approved by both firm’s boards. The $604m price tag would double the size of Collegium’s product portfolio.
You may also be interested in...
Public Company Edition: Mineralys launches the second $100m-plus initial public offering of 2023 and trades higher in its first day. Also, Collegium sells $210m worth of notes, Eliem cuts 55% of its jobs at it shifts to preclinical and Aligos de-prioritizes hepatitis B while reducing its workforce another 10%.
In the month ahead, Japanese firms are set to be hit with further price cuts to their generics, while Eagle Pharmaceuticals will throw off the restraints for its Pemfexy (pemetrexed) 505(b)(2) version of Eli Lilly’s Alimta.
AbbVie pays $130m up front with up to $870m in earnout potential for UCB spinout focused on SV2A modulators. BioNTech gets rights to preclinical TCR candidates for solid tumors from Medigene.